Literature DB >> 31864837

Predictive validity of conversion from the clinical high risk syndrome to frank psychosis.

Laura A Yoviene Sykes1, Maria Ferrara2, Jean Addington3, Carrie E Bearden4, Kristin S Cadenhead5, Tyrone D Cannon6, Barbara A Cornblatt7, Diana O Perkins8, Daniel H Mathalon9, Larry J Seidman10, Ming T Tsuang5, Elaine F Walker11, Thomas H McGlashan12, Kristen A Woodberry13, Albert R Powers12, Allison N Ponce12, John D Cahill12, Jessica M Pollard12, Vinod H Srihari12, Scott W Woods12.   

Abstract

Although the clinical high risk for psychosis (CHR) paradigm has become well-established over the past two decades, one key component has received surprisingly little investigative attention: the predictive validity of the criteria for conversion or transition to frank psychosis. The current study evaluates the predictive validity of the transition to psychosis as measured by the Structured Interview for Psychosis-Risk Syndromes (SIPS) in CHR individuals. Participants included 33 SIPS converters and 399 CHR non-converters both from the North American Prodromal Longitudinal Study (NAPLS-2), as well as a sample of 67 separately ascertained first-episode psychosis (FEP) patients from the STEP program. Comparisons were made at baseline and one-year follow-up on demographic, diagnostic stability (SCID), and available measurement domains relating to severity of illness (psychotropic medication, psychosocial treatment, and resource utilization). Principal findings are: 1) a large majority of cases in both SIPS converters (n = 27/33, 81.8%) and FEP (n = 57/67, 85.1%) samples met criteria for continued psychosis at one-year follow-up; 2) follow-up prescription rates for current antipsychotic medication were higher in SIPS converters (n = 17/32, 53.1%) compared to SIPS non-converters (n = 81/397, 20.4%), and similar as compared to FEP cases (n = 39/65, 60%); and 3) at follow-up, SIPS converters had higher rates of resource utilization (psychiatric hospitalizations, day hospital admissions, and ER visits) than SIPS non-converters and were similar to FEP in most categories. The results suggest that the SIPS definition of psychosis onset carries substantial predictive validity. Limitations and future directions are discussed.
Copyright © 2019 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Predictive validity; SIPS; Transition

Mesh:

Year:  2019        PMID: 31864837      PMCID: PMC7239715          DOI: 10.1016/j.schres.2019.12.002

Source DB:  PubMed          Journal:  Schizophr Res        ISSN: 0920-9964            Impact factor:   4.939


  71 in total

1.  Cost-effectiveness measures, methods, and policy implications from the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for schizophrenia.

Authors:  Robert A Rosenheck; Jeffrey A Lieberman
Journal:  J Clin Psychiatry       Date:  2007-02       Impact factor: 4.384

2.  The "prodromal" patient: both symptomatic and at-risk.

Authors:  S W Woods; T J Miller; T H McGlashan
Journal:  CNS Spectr       Date:  2001-03       Impact factor: 3.790

3.  Comorbid diagnoses for youth at clinical high risk of psychosis.

Authors:  Jean Addington; Danijela Piskulic; Lu Liu; Jonathan Lockwood; Kristin S Cadenhead; Tyrone D Cannon; Barbara A Cornblatt; Thomas H McGlashan; Diana O Perkins; Larry J Seidman; Ming T Tsuang; Elaine F Walker; Carrie E Bearden; Daniel H Mathalon; Scott W Woods
Journal:  Schizophr Res       Date:  2017-03-31       Impact factor: 4.939

4.  'At-risk' for psychosis research: where are we heading?

Authors:  A Lin; B Nelson; A R Yung
Journal:  Epidemiol Psychiatr Sci       Date:  2012-07-30       Impact factor: 6.892

5.  Progressive brain structural changes mapped as psychosis develops in 'at risk' individuals.

Authors:  Daqiang Sun; Lisa Phillips; Dennis Velakoulis; Alison Yung; Patrick D McGorry; Stephen J Wood; Theo G M van Erp; Paul M Thompson; Arthur W Toga; Tyrone D Cannon; Christos Pantelis
Journal:  Schizophr Res       Date:  2009-01-12       Impact factor: 4.939

6.  Association of Hippocampal Glutamate Levels With Adverse Outcomes in Individuals at Clinical High Risk for Psychosis.

Authors:  Matthijs G Bossong; Mathilde Antoniades; Matilda Azis; Carly Samson; Beverley Quinn; Ilaria Bonoldi; Gemma Modinos; Jesus Perez; Oliver D Howes; James M Stone; Paul Allen; Philip McGuire
Journal:  JAMA Psychiatry       Date:  2019-02-01       Impact factor: 21.596

7.  Progressive Decline in Hippocampal CA1 Volume in Individuals at Ultra-High-Risk for Psychosis Who Do Not Remit: Findings from the Longitudinal Youth at Risk Study.

Authors:  New Fei Ho; Daphne J Holt; Mike Cheung; Juan Eugenio Iglesias; Alex Goh; Mingyuan Wang; Joseph Kw Lim; Joshua de Souza; Joann S Poh; Yuen Mei See; Alison R Adcock; Stephen J Wood; Michael Wl Chee; Jimmy Lee; Juan Zhou
Journal:  Neuropsychopharmacology       Date:  2017-01-12       Impact factor: 7.853

8.  Networks of blood proteins in the neuroimmunology of schizophrenia.

Authors:  Clark D Jeffries; Diana O Perkins; Margot Fournier; Kim Q Do; Michel Cuenod; Ines Khadimallah; Enrico Domenici; Jean Addington; Carrie E Bearden; Kristin S Cadenhead; Tyrone D Cannon; Barbara A Cornblatt; Daniel H Mathalon; Thomas H McGlashan; Larry J Seidman; Ming Tsuang; Elaine F Walker; Scott W Woods
Journal:  Transl Psychiatry       Date:  2018-06-06       Impact factor: 6.222

9.  Towards a Standard Psychometric Diagnostic Interview for Subjects at Ultra High Risk of Psychosis: CAARMS versus SIPS.

Authors:  P Fusar-Poli; M Cappucciati; G Rutigliano; T Y Lee; Q Beverly; I Bonoldi; J Lelli; S J Kaar; E Gago; M Rocchetti; R Patel; V Bhavsar; S Tognin; S Badger; M Calem; K Lim; J S Kwon; J Perez; P McGuire
Journal:  Psychiatry J       Date:  2016-05-30

10.  Cortical GABA in Subjects at Ultra-High Risk of Psychosis: Relationship to Negative Prodromal Symptoms.

Authors:  Gemma Modinos; Fatma Simsek; Jamie Horder; Matthijs Bossong; Ilaria Bonoldi; Matilda Azis; Jesus Perez; Matthew Broome; David J Lythgoe; James M Stone; Oliver D Howes; Declan G Murphy; Anthony A Grace; Paul Allen; Philip McGuire
Journal:  Int J Neuropsychopharmacol       Date:  2018-02-01       Impact factor: 5.176

View more
  7 in total

1.  Early Intervention Services for Schizophrenia: Looking Back and Looking Ahead.

Authors:  Vinod H Srihari; Matcheri S Keshavan
Journal:  Schizophr Bull       Date:  2022-05-07       Impact factor: 7.348

2.  Timing of cannabis exposure relative to prodrome and psychosis onset in a community-based first episode psychosis sample.

Authors:  Emily R Kline; Maria Ferrara; Fangyong Li; Deepak Cyril D'Souza; Matcheri Keshavan; Vinod H Srihari
Journal:  J Psychiatr Res       Date:  2022-01-16       Impact factor: 4.791

3.  First help-seeking attempt before and after psychosis onset: measures of delay and aversive pathways to care.

Authors:  Maria Ferrara; Sinan Guloksuz; Walter S Mathis; Fangyong Li; I-Hsin Lin; Sumaiyah Syed; Keith Gallagher; Jai Shah; Emily Kline; Cenk Tek; Matcheri Keshavan; Vinod H Srihari
Journal:  Soc Psychiatry Psychiatr Epidemiol       Date:  2021-05-04       Impact factor: 4.519

4.  Real-world long-term outcomes in individuals at clinical risk for psychosis: The case for extending duration of care.

Authors:  Paolo Fusar-Poli; Andrea De Micheli; Lorenzo Signorini; Helen Baldwin; Gonzalo Salazar de Pablo; Philip McGuire
Journal:  EClinicalMedicine       Date:  2020-10-07

Review 5.  Establishing a clinical service to prevent psychosis: What, how and when? Systematic review.

Authors:  Gonzalo Salazar de Pablo; Andrés Estradé; Marcello Cutroni; Olivier Andlauer; Paolo Fusar-Poli
Journal:  Transl Psychiatry       Date:  2021-01-13       Impact factor: 6.222

6.  Reducing the Duration of Untreated Psychosis (DUP) in a US Community: A Quasi-Experimental Trial.

Authors:  Vinod H Srihari; Maria Ferrara; Fangyong Li; Emily Kline; Sinan Gülöksüz; Jessica M Pollard; John D Cahill; Walter S Mathis; Laura Yoviene Sykes; Barbara C Walsh; Glen McDermott; Larry J Seidman; Ralitza Gueorguieva; Scott W Woods; Cenk Tek; Matcheri S Keshavan
Journal:  Schizophr Bull Open       Date:  2022-01-04

7.  Negative Prognostic Effect of Baseline Antipsychotic Exposure in Clinical High Risk for Psychosis (CHR-P): Is Pre-Test Risk Enrichment the Hidden Culprit?

Authors:  Andrea Raballo; Michele Poletti; Antonio Preti
Journal:  Int J Neuropsychopharmacol       Date:  2021-09-21       Impact factor: 5.176

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.